Terminal / Weight Loss

Survodutide

Phase 3

aka BI 456906

Dual GLP-1/glucagon agonist in phase 3 for obesity and fatty liver.

Mechanism

Activates GLP-1 and glucagon receptors: appetite down, energy expenditure up. The glucagon arm is also why it's being pushed hard for MASH, the serious fatty-liver disease.

Regulatory & Safety Status

Investigational (Boehringer Ingelheim and Zealand Pharma). Not approved.

Research

2026Obesity reviews : an official journal of the International Association for the Study of Obesity

The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus

2026Diabetes, obesity & metabolism

Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease

2026Contemporary clinical trials

Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties

2026The New England journal of medicine

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes

2024PubMed

Latest survodutide research

Related Compounds

Weight Loss

Retatrutide

Phase 3

Triple agonist (GLP-1, GIP, glucagon) in phase 3 for obesity. The one everyone's watching.

Weight Loss

Tirzepatide

Approved

Approved dual agonist (GLP-1 and GIP). Currently the strongest thing you can get with a prescription.